PAN mentioned in Bloomberg Law on Medicare Part D utilization management
Information about this website: Following the March 2026 merger of Patient Advocate Foundation and the PAN Foundation, this website is now a part of Patient Advocate Foundation and remains active during our website transition.
Where to find information during our transition:
- About the merged organization: uniting.patientadvocate.org
- Financial assistance: totalassist.org
- Additional direct patient services and resources: patientadvocate.org
- Education: panfoundation.org and education.patientadvocate.org
- Clinical trials education: clinicaltrials.panfoundation.org
- Advocacy: npaf.org
- Research: patientinsightinstitute.org
While patient-friendly provisions of the Inflation Reduction Act—including a Part D $2,000 cap on annual out-of-pocket expenses—take effect in 2025, finance and policy experts predict that drug plans will try to manage their rising costs by increasing utilization management practices such as step therapy, prior authorization requirements, and switching patients to less expensive medications.
The PAN Foundation is mentioned in an article in Bloomberg Law as one of the patient advocacy groups urging Congress to streamline utilization management practices instead of increasing them.
Cost-cutting utilization management practices by Part D drug plans could delay treatments for patients, and cause some to lose coverage altogether. PAN and patient advocacy allies have urged the administration and Centers for Medicare & Medicaid Services (CMS) to implement guardrails to prevent utilization management abuse as a reaction to the Medicare reforms.